Epidermal growth factor receptor tyrosine kinase inhibitors plus chemotherapy: Case closed or is the jury still out?

被引：57

作者：

Gandara, DR ^{[1
]}

Gumerlock, PH ^{[1
]}

机构：

[1] Univ Calif Davis, Ctr Canc, Sacramento, CA 95817 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 25期

关键词：

D O I：

10.1200/JCO.2005.05.030

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：5856 / 5858

页数：3

共 18 条

[1]

[Anonymous], P AM SOC CLIN ONCOL

[2] Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: Effects on survival and quality of life [J].

Cullen, MH ;

Billingham, LJ ;

Woodroffe, CM ;

Chetiyawardana, AD ;

Gower, NH ;

Joshi, R ;

Ferry, DR ;

Rudd, RM ;

Spiro, SG ;

Cook, JE ;

Trask, C ;

Bessell, E ;

Connolly, CK ;

Tobias, J ;

Souhami, RL .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (10) :3188-3194

[3]

Davies AM, 2005, J CLIN ONCOL, V23, p630S

[4] Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib [J].

Eberhard, DA ;

Johnson, BE ;

Amler, LC ;

Goddard, AD ;

Heldens, SL ;

Herbst, RS ;

Ince, WL ;

Jänne, PA ;

Januario, T ;

Johnson, DH ;

Klein, P ;

Miller, VA ;

Ostland, MA ;

Ramies, DA ;

Sebisanovic, D ;

Stinson, JA ;

Zhang, YR ;

Seshagiri, S ;

Hillan, KJ .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) :5900-5909

[5] Bronchioloalveolar carcinoma: A model for investigating the biology of epidermal growth factor receptor inhibition [J].

Gandara, DR ;

West, H ;

Chansky, K ;

Davies, AM ;

Lau, DHM ;

Crowley, J ;

Gumerlock, PH ;

Hirsch, FR ;

Franklin, WA .

CLINICAL CANCER RESEARCH, 2004, 10 (12) :4205S-4209S

[6]

Gatzemeier U, 2004, J CLIN ONCOL, V22, p619S

[7] Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT1 [J].

Giaccone, G ;

Herbst, RS ;

Manegold, C ;

Scagliotti, G ;

Rosell, R ;

Miller, V ;

Natale, RB ;

Schiller, JH ;

von Pawel, J ;

Pluzanska, A ;

Gatzemeier, M ;

Grous, J ;

Ochs, JS ;

Averbuch, SD ;

Wolf, MK ;

Rennie, P ;

Fandi, A ;

Johnson, DH .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) :777-784

[8] Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 2 [J].

Herbst, RS ;

Giaccone, G ;

Schiller, JH ;

Natale, RB ;

Miller, V .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) :785-794

[9] TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer [J].

Herbst, RS ;

Prager, D ;

Hermann, R ;

Fehrenbacher, L ;

Johnson, BE ;

Sandler, A ;

Kris, MG ;

Tran, HT ;

Klein, P ;

Li, X ;

Ramies, D ;

Johnson, DH ;

Miller, VA .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) :5892-5899

[10]

Hirsch FR, 2005, J CLIN ONCOL, V23, p628S

← 1 2 →